North America Blau Syndrome Market, By Therapeutic Areas (Skin Rash, Inflammation), Route of Administration (Oral, Parenteral, Topical, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
North America Blau Syndrome Market Analysis and Size
Several advancements in the health care industry of blau syndrome will impact in launching new product by the several manufacturers into the market, improving its demand along with availability of off-label drugs. Furthermore, everyday changing technologies also puts a hindrance for physicians to perform the numerous kinds of genetic tests. Presently, numerous research studies are taking place which is projected to create a competitive advantage for manufacturers to develop advanced and innovative blau syndrome drugs which is projected to provide several other opportunities in the blau syndrome market.
Data Bridge Market Research analyses a growth rate in the blau syndrome market in the forecast period 2023-2030. The expected CAGR of north america blau syndrome market is tend to be around 12.8% in the mentioned forecast period. The market is valued at USD 3.94 million in 2022, and it will grow upto USD 10.33 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
North America Blau Syndrome Market Scope and Segmentation
Report Metric
Details
Forecast Period
2023 to 2030
Base Year
2022
Historic Years
2021 (Customizable to 2015 - 2020)
Quantitative Units
Revenue in USD Million, Volumes in Units, Pricing in USD
Segments Covered
Therapeutic Areas (Skin Rash, Inflammation), Route of Administration (Oral, Parenteral, Topical, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
Countries Covered
U.S., Canada and Mexico in North America
Market Players Covered
Abbvie, Inc (U.S.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel), Pfizer Inc. (U.S.), Amgen Inc. (U.S.), Janssen North America Services, LLC (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Hikma Pharmaceuticals PLC (U.K.), Fulgent Genetics (U.S.), Invitae Corporation (U.S.), Swedish Orphan Biovitrum AB (Sweden), Alkem Labs Ltd (India), Accord Healthcare (U.K.), Zydus Group (India), Amneal Pharmaceutical Inc. (U.K.), CENTOGENE N.V. (Germany)
Market Opportunities
Growing Treatment Options
Increasing Product Launches and Developments
Market Definition
Blau Syndrome typically presents in childhood with granulomatous dermatitis, arthritis, and uveitis. This syndrome is also termed as familial juvenile systemic granulomatosis. Even though a skin rash is not necessarily a ubiquitous feature of Blau syndrome, it is mostly the first sign of disease if it is available. In majority of the cases, a normal rash appears within the first year of life and presents as discrete, erythematous papules. In this condition, the most common feature which is arthritis, tends to rise between the ages of 2 to 4 years.
North America Blau Syndrome Market Dynamics
Drivers
Increasing Diagnostic Procedures
There has been increasing diagnostic procedures that are available which boosts the market growth. Optical coherence tomography (OCT) may be used to depict the extent of ocular disease. Skin or synovial biopsy may be used that will reveal noncaseating granulomas. Out of these two options, skin biopsy is less invasive and has showed higher accuracy. Furthermore, next generation sequencing may be used to test for causative NOD2 mutations, that will confirm the diagnosis. X-rays show dysplastic changes, such as camptodactyly, carpal dysplasia, abnormal ulna and second metacarpal bone shape, abnormal distal radial epiphysis, short ulna. Complete blood count (CBC), C-reactive protein (CRP), serum angiotensin-converting enzyme (ACE), erythrocyte sedimentation rate (ESR), antinuclear antibody (ANA), anti-neutrophilic cytoplasmic antibody (ANCA), anti-dsDNA antibody, Lyme disease serology, rheumatoid factor (RF), RPR/VDRL, human leukocyte antigen (HLA) testing, tuberculin skin test, pathergy skin test are the types of tests that can be performed.
Opportunities
Growing Treatment Options
Treatment options such as corticosteroids also have utility during quiescent periods. The prolonged need for corticosteroids and the frequency of refractory symptoms signify the use of immunosuppressants such as mycophenolate mofetil, methotrexate, or azathioprine. For this reason, the wide use of monoclonal antibodies to target these cytokines has become helpful; though, variable degrees of efficacy have been witnessed in the literature. It is difficult to determine the true therapeutic benefit of these agents due to contrasting results and the relatively scarce amount of data available. Though medical management is the keystone of treatment for patients with Blau syndrome, operative intervention is also used in certain scenarios. There are many ocular diseases, wherein many inflammatory sequelae should be addressed surgically. Patients may opt to undergo joint fusion procedures because of severe, unrelenting arthritis. Thus, this boosts the market growth.
Restraints/Challenges
Unavailability of skilled professionals
The wide unavailability of qualified professionals who cannot treat the patients with appropriate treatments could restrict the market growth during the forecast period 2023-2030.
High Cost of Treatment
The increasing expenditure related with the medications hinder the market growth. These inhibitors cost high and people in the developing and underdeveloped countries can lead to the under treatment of numerous patients. This hinders the market growth.
This blau syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the blau syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
In 2020, Oncodesign got product selection approval for ODS-101 RIPK2 inhibitor, which is an enzyme mainly responsible for producing an innate immune response. Furthermore, RIPK2 activates the NOD signaling, henceforth proving to be an efficient drug target for treatment of Blau syndrome. This product selection aided the company in putting its foot in market for the treatment of Blau syndrome.
In 2019, CENTOGENE collaborated with Pfizer Inc., according to which CENTOGENE will provide genetic information associated with rare disease involving Blau syndrome to Pfizer. This agreement aided the company to increase the growth of its market for rare disease.
North America Blau Syndrome Market Scope
The blau syndrome market is segmented on the basis of therapeutic areas, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Therapeutic Areas
Skin Rash
Inflammation
Route of Administration
Oral
Parenteral
Topical
Others
End User
Hospitals
Homecare
Specialty Clinics
Others
Distribution Channel
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Blau Syndrome Market Regional Analysis/Insights
The blau syndrome market is analyzed and market size insights and trends are provided by therapeutic areas, route of administration, end-users and distribution channel as referenced above.
The major countries covered in the North America blau syndrome market reportare U.S., Canada and Mexico in North America.
U.S. is leading the market due to the increasing generic market and growing demand for all types of treatment for the same.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and North America Blau Syndrome Market Share Analysis
The blau syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, north america presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to blau syndrome market
Key players operating in the blau syndrome market include:
Abbvie, Inc (U.S.)
Novartis AG (Switzerland)
Teva Pharmaceutical Industries Ltd (Israel)
Pfizer Inc.(U.S.)
Amgen Inc. (U.S.)
Janssen North america Services, LLC (U.S.)
F. Hoffmann-La Roche Ltd. (Switzerland)
Mylan N.V. (U.S.)
Hikma Pharmaceuticals PLC (U.K.)
Fulgent Genetics (U.S.)
Invitae Corporation (U.S.)
Swedish Orphan Biovitrum AB (Sweden)
Alkem Labs Ltd (India)
Accord Healthcare (U.K.)
Zydus Group (India)
Amneal Pharmaceutical Inc. (U.K.)
CENTOGENE N.V. (Germany)
SKU-55592
Get online access to the report on the World's First Market Intelligence Cloud
Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
Claudio Rondena
Group Business Development & Strategic Marketing Director, C.O.C Farmaceutici SRL
"This morning we were involved in the first part, the data presentation of MKT analysis, selected abstract from your work. The board team was really impressed and very appreciated, as well."
David Manning - Thermo Fisher Scientific
Director, Global Strategic Accounts,
Dear Ricky, I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice.
Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough.
Your work is much appreciated.
Manager - Market Analytics,
Uriah D. Avila - Zeus Polymer Solutions
Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.
Business Development Manager,
(Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC
DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.
Business Intelligence and Analytics,
Ipsen Biopharm Limited
We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.
Competition Analyst,
Basler Web
I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.
Marketing Director,
Buhler Group
It was indeed a good experience, would definitely recommend and come back for future prospects.
COO,
A global leader providing Drug Delivery Services
DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.
Marketing Director,
Philips Healthcare
The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.
Product manager,
Fujifilms
Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.
Investor relations,
GE Healthcare
Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.
Market Analyst,
Medincell
We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.
Andrew - Senior Global Marketing Manager,
Medtronic (US)
I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.
Amarildo - Manager, Global Strategic Alignment
MasterCard
We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.
Tor Hammer
Green Nexus LLc
Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects
I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying.
Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.
Yuki Kopyl (Asian Business Development Department)
UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)
Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future